ADVERTISEMENT
For decades, aspirin has been a go-to medication for its blood-thinning properties, widely recommended to prevent heart attacks and strokes, particularly in older adults. However, recent research has raised concerns about the safety of this common treatment, particularly in older populations.
New studies suggest that even low doses of aspirin may increase the risk of brain bleeds (hemorrhagic strokes), prompting experts to re-evaluate its widespread use as a preventive measure.
Advertisement
The Aspirin Dilemma: A Historical Overview
Aspirin, or acetylsalicylic acid, has been used for over a century for its anti-inflammatory, analgesic, and antipyretic properties. Over the last several decades, it became especially popular in low doses (often between 75–100 mg daily) to reduce the risk of cardiovascular diseases. The idea behind this therapy is aspirin’s ability to inhibit platelet aggregation, which reduces the likelihood of blood clots forming in arteries, potentially preventing heart attacks and ischemic strokes (caused by clots blocking blood flow to the brain).
However, despite its benefits in preventing clot-related conditions, aspirin’s impact on the body’s clotting ability can also lead to unintended consequences. Specifically, it can make patients more susceptible to bleeding, especially in the gastrointestinal tract and the brain.
The New Findings: Aspirin and Brain Bleeds
A number of recent studies have shifted the conversation regarding aspirin's risks, especially for older adults. A key study published in 2023 in The BMJ analyzed data from multiple clinical trials involving older adults. It found that low-dose aspirin was associated with a 37% increase in the risk of intracranial hemorrhage (brain bleed) compared to those not taking the medication. The bleeding risk appeared to be higher in individuals over 70, especially those with no history of cardiovascular disease.
Dr. Mark Wood, a neurologist from Johns Hopkins University, commented on these findings, stating, "Aspirin’s role as a preventive treatment needs to be reconsidered for certain populations, particularly older adults who are at greater risk of adverse effects. The risks might outweigh the benefits for those without a significant history of heart attack or stroke."
Another large-scale trial, the ASPREE (Aspirin in Reducing Events in the Elderly) trial, conducted in the United States and Australia, focused on adults over the age of 70. Published in The New England Journal of Medicine in 2022, the ASPREE study provided robust evidence that older adults taking low-dose aspirin had a higher incidence of major hemorrhagic events, including brain bleeds, compared to a placebo group. The study's authors concluded that for otherwise healthy older individuals, the use of aspirin as a preventive measure was not only ineffective in prolonging life or reducing disability but also increased the likelihood of dangerous bleeding events.
Why Older Adults Are at Higher Risk
The higher risk of brain bleeds in older adults can be attributed to several factors. First, the walls of blood vessels naturally become more fragile with age, making them more susceptible to rupture. Combined with the blood-thinning effects of aspirin, this can increase the likelihood of bleeding inside the brain. Additionally, as people age, their kidneys and liver—the organs responsible for metabolizing and excreting drugs—become less efficient, which can heighten the effects of medications and increase risks of complications.
Other health conditions, such as hypertension (high blood pressure), also compound the risk. High blood pressure weakens blood vessel walls, and when combined with aspirin, it can lead to an elevated chance of intracranial hemorrhage.
Continued on the next page
ADVERTISEMENT
